Allergan Gets Regen Med Assets, Acelity Gets Cash Boost Post-IPO Dump

21 Dec 2016

• By Mandy Jackson and Tina Tan

Allergan has agreed to acquire Acelity's LifeCell division for $2.9bn. The deal will give Allergan entry to the regenerative medicine sector and expand its aesthetics portfolio, while the substantial cash consideration should console Acelity after ditching plans for an IPO.

Allergan PLC will pay Acelity LP Inc. $2.9bn to buy the LifeCell Corp. portfolio of aesthetic and surgical products. The all-cash deal not only marks Allergan’s first regenerative medicine transaction – and one that is accretive to the specialty pharma company's top- and bottom-line, it will also provide Acelity with an alternative source of new capital now that the firm has finally quashed its long-held hopes for an IPO.

The LifeCell purchase gives Allergan a suite of commercial products for what chief commercial officer William Meury describes as the...